According to a recent LinkedIn post from Araceli Biosciences, the company is actively engaging attendees at the SLAS conference, highlighting its participation on day two. The post emphasizes positive attendee reactions to an innovation spotlight featuring 3D imaging of organoid growth at ultra high throughput speeds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also references scientific work presented by Virneliz Fernandez-Vega from the Spicer Lab at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology on organoid growth analysis. This association with advanced organoid research may strengthen Araceli Biosciences’ positioning in high-content imaging and drug discovery workflows.
By inviting visitors to booth #2312 to see the Endeavor Ultra run live, the post suggests a focus on hands-on product demonstrations and lead generation among a specialized scientific audience. For investors, such visibility at SLAS could indicate ongoing efforts to expand the company’s customer base, validate its technology with key opinion leaders, and potentially support future revenue growth in high-throughput imaging solutions.